image
Inovio Pharmaceuticals, Inc. INO
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 1.42
1.46 %
$ 52.1 M
Market Cap
-0.44
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one INO stock under the worst case scenario is HIDDEN Compared to the current market price of 1.42 USD, Inovio Pharmaceuticals, Inc. is HIDDEN

INO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one INO stock under the base case scenario is HIDDEN Compared to the current market price of 1.42 USD, Inovio Pharmaceuticals, Inc. is HIDDEN

INO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one INO stock under the best case scenario is HIDDEN Compared to the current market price of 1.42 USD, Inovio Pharmaceuticals, Inc. is HIDDEN

INO Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart INO

image
1M -36%
6M -46%
1Y -663%
3Y -1599%
5Y -18415%
All
$2.3$2.3$2.2$2.2$2.1$2.1$2.0$2.0$1.9$1.9$1.8$1.8$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
218 K REVENUE
-73.83%
Growth Rates
1Year -73.83%
3Years -50.31%
5Years -44.44%
7Years -52.88%
10Years -32.10%
-112 M OPERATING INCOME
21.91%
Growth Rates
1Year 21.91%
3Years 28.01%
5Years -0.23%
7Years -4.31%
10Years -11.03%
-107 M NET INCOME
20.62%
Growth Rates
1Year 20.62%
3Years 29.31%
5Years 2.31%
7Years -2.83%
10Years -11.49%
-104 M OPERATING CASH FLOW
16.31%
Growth Rates
1Year 16.31%
3Years 21.57%
5Years -1.24%
7Years -7.38%
10Years -13.31%
104 M INVESTING CASH FLOW
19.13%
Growth Rates
1Year 19.13%
3Years 37.39%
5Years 68.31%
7Years 28.35%
10Years 17.24%
51.5 M FINANCING CASH FLOW
930.52%
Growth Rates
1Year 930.52%
3Years -37.56%
5Years -13.35%
7Years -8.48%
10Years -3.36%
0 REVENUE
0.00%
Growth Rates
1Year -73.83%
3Years -50.31%
5Years -44.44%
7Years -52.88%
10Years -32.10%
-25.1 B OPERATING INCOME
-122880.21%
Growth Rates
1Year 21.91%
3Years 28.01%
5Years -0.23%
7Years -4.31%
10Years -11.03%
-19.7 B NET INCOME
-101515.02%
Growth Rates
1Year 20.62%
3Years 29.31%
5Years 2.31%
7Years -2.83%
10Years -11.49%
-26.9 B OPERATING CASH FLOW
-136566.76%
Growth Rates
1Year 16.31%
3Years 21.57%
5Years -1.24%
7Years -7.38%
10Years -13.31%
-51.8 M INVESTING CASH FLOW
-149.38%
Growth Rates
1Year 19.13%
3Years 37.39%
5Years 68.31%
7Years 28.35%
10Years 17.24%
1.03 B FINANCING CASH FLOW
3426.90%
Growth Rates
1Year 930.52%
3Years -37.56%
5Years -13.35%
7Years -8.48%
10Years -3.36%
Balance Sheet Inovio Pharmaceuticals, Inc.
image
Current Assets 97.8 M
Cash & Short-Term Investments 94.1 M
Receivables 1.2 M
Other Current Assets 2.52 M
Non-Current Assets 17.1 M
Long-Term Investments 1.61 M
PP&E 11.8 M
Other Non-Current Assets 3.68 M
81.91 %10.25 %3.21 %Total Assets$114.9m
Current Liabilities 35.3 M
Accounts Payable 6.44 M
Short-Term Debt 2.5 M
Other Current Liabilities 26.4 M
Non-Current Liabilities 11.1 M
Long-Term Debt 9.37 M
Other Non-Current Liabilities 1.7 M
13.89 %5.38 %56.87 %20.19 %3.67 %Total Liabilities$46.4m
EFFICIENCY
Earnings Waterfall Inovio Pharmaceuticals, Inc.
image
Revenue 218 K
Cost Of Revenue 3.13 M
Gross Profit -2.91 M
Operating Expenses 111 M
Operating Income -112 M
Other Expenses -5.14 M
Net Income -107 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)218k(3m)(3m)(111m)(112m)5m(107m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-1337.41% GROSS MARGIN
-1337.41%
Averages
1Year -1337.41%
3Years -537.35%
5Years -590.05%
7Years -698.69%
10Years -459.08%
-51616.91% OPERATING MARGIN
-51616.91%
Averages
1Year -51616.91%
3Years -23841.51%
5Years -18034.22%
7Years -13311.70%
10Years -9368.01%
-49254.27% NET MARGIN
-49254.27%
Averages
1Year -49254.27%
3Years -22765.76%
5Years -17681.31%
7Years -13093.78%
10Years -9214.58%
-0.16% ROE
-0.16%
Averages
1Year -0.16%
3Years -81.55%
5Years -73.54%
7Years -569.81%
10Years -412.70%
-94.75% ROA
-94.75%
Averages
1Year -94.75%
3Years -85.44%
5Years -71.55%
7Years -73.64%
10Years -61.87%
-0.14% ROIC
-0.14%
Averages
1Year -0.14%
3Years -68.88%
5Years -61.89%
7Years -72.45%
10Years -63.59%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inovio Pharmaceuticals, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -107 M
Depreciation & Amortization 3.13 M
Capital Expenditures -488 K
Stock-Based Compensation 6.6 M
Change in Working Capital -2.66 M
Others -4.39 M
Free Cash Flow -105 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inovio Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for INO of $16 , with forecasts ranging from a low of $4 to a high of $40 .
INO Lowest Price Target Wall Street Target
4 USD 181.69%
INO Average Price Target Wall Street Target
16 USD 1026.76%
INO Highest Price Target Wall Street Target
40 USD 2716.90%
Price
Max Price Target
Min Price Target
Average Price Target
40403535303025252020151510105500Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.069 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.1400.1400.1200.1200.1000.1000.0800.0800.0600.0600.0400.0400.0200.0200.0000.0000.0690.0690.140.0690.070.0690.0720172017
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Inovio Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INOVIO to Present at Upcoming Scientific Conference PLYMOUTH MEETING, Pa. , July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Summit in Boston, Massachusetts. prnewswire.com - 2 weeks ago
INOVIO Announces Pricing of $25 Million Public Offering PLYMOUTH MEETING, Pa. , July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock and Series B warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock, at a combined public offering price of $1.75 per share of common stock and accompanying Series A and Series B warrants. prnewswire.com - 3 weeks ago
INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, Pa. , July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering. prnewswire.com - 3 weeks ago
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. globenewswire.com - 3 weeks ago
Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call. seekingalpha.com - 2 months ago
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago. zacks.com - 2 months ago
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25 Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025 INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production Preprint manuscript available on ResearchSquare.com  PLYMOUTH MEETING, Pa. , May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments. prnewswire.com - 2 months ago
Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript) Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference. seekingalpha.com - 2 months ago
INOVIO to Present at Upcoming Scientific and Investor Conferences PLYMOUTH MEETING, Pa. , April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. prnewswire.com - 2 months ago
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 PLYMOUTH MEETING, Pa. , April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. prnewswire.com - 2 months ago
Bet on These 5 Top-Ranked Stocks With Rising P/E Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc. zacks.com - 3 months ago
Inovio (INO) Upgraded to Buy: Here's What You Should Know Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
8. Profile Summary

Inovio Pharmaceuticals, Inc. INO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 52.1 M
Dividend Yield 0.00%
Description Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Contact 660 West Germantown Pike, Plymouth Meeting, PA, 19462 https://www.inovio.com
IPO Date Dec. 8, 1998
Employees 134
Officers Mr. Robert L. Crotty J.D. General Counsel & Chief Compliance Officer Dr. Laurent M. Humeau Ph.D. Chief Scientific Officer & Chairman of the Scientific Advisory Board Thomas Hong Manager of Investor Relations Mr. E. J. Brandreth MBA Senior Vice President of Quality Assurance Mr. Robert J. Juba Jr. Senior Vice President of Biological Manufacturing & Clinical Supply Management Mr. Shawn D. Bridy M.A., M.B.A. Senior Vice President of Business Development Dr. Jeffrey Skolnik Senior Vice President of Clinical Development Mr. Peter D. Kies Chief Financial Officer Dr. Jacqueline E. Shea Ph.D. Chief Executive Officer, President & Director Dr. Michael Sumner M.D. Chief Medical Officer